Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands

Jian Zhong, Xuesong Yang, Junju Chen, Kejun He, Xinya Gao, Xujia Wu, Maolei Zhang, Huangkai Zhou, Feizhe Xiao, Lele An, Xiuxing Wang (), Yu Shi () and Nu Zhang ()
Additional contact information
Jian Zhong: The First Affiliated Hospital of Sun Yat-sen University
Xuesong Yang: The First Affiliated Hospital of Sun Yat-sen University
Junju Chen: The First Affiliated Hospital of Sun Yat-sen University
Kejun He: The First Affiliated Hospital of Sun Yat-sen University
Xinya Gao: The First Affiliated Hospital of Sun Yat-sen University
Xujia Wu: The First Affiliated Hospital of Sun Yat-sen University
Maolei Zhang: The First Affiliated Hospital of Sun Yat-sen University
Huangkai Zhou: The First Affiliated Hospital of Sun Yat-sen University
Feizhe Xiao: The First Affiliated Hospital of Sun Yat-sen University
Lele An: Third Military Medical University (Army Medical University)
Xiuxing Wang: Nanjing Medical University
Yu Shi: Third Military Medical University (Army Medical University)
Nu Zhang: The First Affiliated Hospital of Sun Yat-sen University

Nature Communications, 2022, vol. 13, issue 1, 1-18

Abstract: Abstract Glioblastoma (GBM) is a highly aggressive primary brain tumour and is resistant to nearly all available treatments, including natural killer (NK) cell immunotherapy. However, the factors mediating NK cell evasion in GBM remain largely unclear. Here, we report that EZH2-92aa, a protein encoded by circular EZH2, is overexpressed in GBM and induces the immune evasion of GBM stem cells (GSCs) from NK cells. Positively regulated by DEAD-box helicase 3 (DDX3), EZH2-92aa directly binds the major histocompatibility complex class I polypeptide-related sequence A/B (MICA/B) promoters and represses their transcription; it also indirectly represses UL16-binding protein (ULBP) transcription by stabilizing EZH2. The downregulation of NK group 2D ligands (NKG2DLs, including MICA/B and ULBPs) in GSCs mediates NK cell resistance. Moreover, stable EZH2-92aa knockdown enhances NK cell-mediated GSC eradication in vitro and in vivo and synergizes with anti-PD1 therapy. Our results highlight the immunosuppressive function of EZH2-92aa in inhibiting the NK cell response in GBM and the clinical potential of targeting EZH2-92aa for NK-cell-directed immune therapy.

Date: 2022
References: View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-32311-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32311-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-32311-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().